Coagulation parameters in HIV
Completed
- Conditions
- HIV, thrombophilia
- Registration Number
- NL-OMON20034
- Lead Sponsor
- none
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 39
Inclusion Criteria
Inclusion in the original INF-BEAST study
Exclusion Criteria
Declining informed consent to participate in the INF-BEAST2 study
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Plasma levels of following markers:<br>- FVIII <br>- Anti-thrombin<br>- Protein C antigen<br>- Protein S antigen<br>- Free protein S<br>- Fibrinogen<br>- Lupus anticoagulans<br>- Von Willebrand factor<br>- D-dimer
- Secondary Outcome Measures
Name Time Method - Lipid plasma levels (including cholesterol, HDL- and LDL cholesterol and triglycerides)<br>- The occurrence of cardiovascular events (including myocardial infarction, cerebrovascular accidents, peripheral arterial disease, arterial thrombosis) and venous thrombosis at any site
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link HIV-1 and long-term cART to thrombophilia and cardiovascular risk markers?
How does cART-induced inflammation affect coagulation parameters in HIV-1 patients compared to standard-of-care regimens?
Which biomarkers (e.g., D-dimer, von Willebrand factor) predict cardiovascular disease progression in NL-OMON20034 HIV cohort?
What adverse coagulation events are associated with prolonged cART use in HIV-1 patients and how are they managed?
How do antithrombotic strategies like rivaroxaban or enoxaparin compare to cART in mitigating HIV-related thrombophilia risks?